Articles On Dimerix (ASX:DXB)

Source: Guschenkova, Shutterstock Summary Dimerix Limited made substantial progress on the operational front during the third quarter. The Company focussed on clinical trials advancement to offer treatments worldwide for patients havi...

The company is keeping its eye on the prize as it builds towards longer-term studies for its DMX-200 treatment solution to DKD. Biotech company Dimerix (ASX:DXB) has a number of irons in the fire as it moves through multiple Phase 3 trials...

Wall Street subdued, as bank stocks feel the heat Dow Jones rose slightly by 0.3%, while S&P 500 and NASDAQ fell by 0.09% and 0.6% respectively. Banks stocks were the main casualties, as Nomura and Credit Suisse both said they were faci...

Source:Vintage Tone, Shutterstock Summary Dimerix has completed a study to confirm the nasogastric tube delivery of DMX-200 in COVID-19 patient admitted to ICU. ASX-listed medicinal cannabis player ECS Botanic enters into another medi...

Source:ShutterstockProfessional,Shutterstock Summary Dimerix revealed that in-vitro study data demonstrate DMX-200 with endothelin A inhibitors shows greater potency and efficacy. A worldwide leader in drone security technology DroneS...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

The Dimerix Ltd (ASX: DXB) share price is rising today after the biopharmaceutical company announced its involvement in a trial on COVID-19 therapies. Dimerix will be involved in the trial, named CLARITY 2.0, which has received approval fr...

Special Report: Final clinical trial approval is expected by April for the study, in which Dimerix’s DMX-200 treatment plays a ... Read More The post Global CLARITY 2.0 study gets key approval from Indian regulators for clinical COVID-19 st...

Source: S_L ,Shutterstock Summary Dimerix Limited announced that the CLARITY 2.0 team obtained authorisation from the Central Independent Ethical Review Board. The Company has submitted dossiers for regulatory approvals in India for t...

COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or tests are pushing on. The outbreak of the pandemic caused a number of ASX companies (big and small) to pivot to fighting COVID-19. In the last f...

Special Report: Dimerix (ASX:DXB) is planning another study evaluating the use of its lead drug candidate to treat diabetic kidney ... Read More The post Dimerix planning longer study of DMX-200 to treat kidney disease appeared first on Sto...

Special Report: Melbourne biotech company Dimerix (ASX:DXB) expects to receive readouts on three phase 3 studies in the near term ... Read More The post Dimerix has three ‘shots on goal’ next year appeared first on Stockhead.

ASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndrome (ARDS). ARDS is a disease that hinders the lungs’ ability to operate and is a major culprit of COVID-19 deaths. Essentially it causes lun...

Clinical-stage company Dimerix (ASX:DXB) has announced its lead candidate DMX-200 will enter a second clinical study in COVID-19 patients.

About 600 participants in India who have tested positive for COVID-19 will be enrolled in the randomised, double blind, placebo-controlled ... Read More The post Second group of researchers to investigate efficacy of Dimerix drug candidate...

The Dimerix Ltd (ASX: DXB) share price lifted higher today after the company announced the start of its second clinical study on lead drug candidate, DMX-200. At the time of writing, the Dimerix share price is up 6.1% at 26 cents. What’s d...

Summary HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US. Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study. Dimerix is confident that...

Special Report: Melbourne biotech company Dimerix (ASX:DXB) is working with independent researchers to ship its lead drug candidate DMX-200 to ... Read More The post Global study will test Dimerix drug compound DMX-200 as COVID-19 treatment...

Special Report: Dimerix is developing a potential treatment for constructive obstructive pulmonary disease (COPD), the fourth-leading cause of death worldwide. ... Read More The post Dimerix’s DMX-700 drug candidate has enormous potential a...

Melbourne biotech release analysis of study that sent share price crashing last month Study showed drug candidate did seem to ... Read More The post Dimerix shares up after analysis on DMX-200 diabetic kidney disease trial results appeared...

Dimerix (ASX:DXB) says it has navigated another important step in the development of its lead compound DMX-200 for the treatment of kidney disease.

Shares of Melbourne-based biotechnology company Dimerix Ltd [ASX:DXB] have gained 9% today, to trade at 32 cents at the time of writing. The DXB share price rose on the back of encouraging results that will support... The post Dimerix Share...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit of progress over the last fortnight, with 64 small-cap life sciences gaining ground and just 52 losing it. Another 15 companies were flat....

Melbourne-based clinical-stage biopharmaceutical company Dimerix (ASX:DSB) has updated on clinical trials of its drug candidate DMX-200 for kidney diseases.

Summary ASX listed clinical-stage healthcare company Dimerix Limited announced positive results in Phase 2 clinical trial of DMX-200 in diabetic kidney disease patients. Following the announcement, Dimerix Limited’s share price fell sha...

A quick wrap of the ASX’s key winners and losers on Monday, September 14. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS Code Na...

Special Report: Dimerix plans to further explore the potential of DMX-200 to treat kidney diseases following the completion of a positive and informative phase-2 trial. Dimerix (ASX:DXB) says it will progress with research on its chemokine...

The Dimerix Ltd (ASX: DXB) share price has plummeted 63.51% today to 27 cents. This came after the drug company reported the results of its phase 2 study of DMX-200 in patients with diabetic kidney disease. Why has the Dimerex share price...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

Melbourne-based biotech company Dimerix Ltd [ASX:DXB] got a shot in the arm recently after being awarded $1 million from the Australian government’s Medical Research Future Fund. This has pushed the DXB share price up 7.14% to trade at 75 c...

Right now investors have a range of areas to choose great ASX shares for growth. On one hand we see radical changes in short term credit with the buy now, pay later companies led by Afterpay Ltd (ASX: APT). On the other hand, changes in th...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

Summary Mesoblast disclosed that the Phase 3 clinical trial of Remestemcel-L is anticipated to complete recruitment in September 2020 in the US. At the end of the quarter ended June 2020, Mesoblast had nearly US$129.3 million cash on ha...

Melbourne-based biopharmaceutical company Dimerix (ASX:DXB) has reported positive results from the clinical trial of its drug candidate DMX-200.

A quick wrap of the ASX’s key winners and losers on Wednesday, July 29. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 529 stocks rose, 801 declined and...

Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often le...

Dimerix’s (ASX: DXB) phase-two trial for focal segmental glomerulosclerosis (FSGS) has met both primary and secondary endpoints, with 86 per cent of patients showing a response to the drug DMX-200 versus placebo. This morning’s news drove t...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

In June, ASX-listed companies of all sizes continued to raise capital but the small-cap sector was particularly busy. Stocks with market capitalisations of under $100m at the time of the deal raised $274m in the last month. This is triple M...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim catches up with CEO and MD of Dimerix, Nina Webster. Dim...

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced the placement of 16,222,580 fully paid ordinary shares to institutional and sophisticated investors at a price of $0.36 per share to raise $5.8 million before...

Special Report: Biotech Dimerix wins over institutional investors as it prepares for a global Phase 3 COVID-19 trial. Hotshot biotech Dimerix (ASX:DXB) is finally on the radar of institutional investors, who bought in for the first time via...

On Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market darling, cobalt has stumbled this year but EV growth is expected to drive demand and prices and is this a new dawn for nickel? But first…   T...

Drug discovery tearaway Dimerix – which is trading up more than 200 per cent in the past six months – is making a trip to equity capital markets. 

Special Report: Dimerix expects results for its FSGS clinical trial in July and says so far, it’s meeting the primary endpoint.    Biotech Dimerix has dosed its last patient in a crucial phase 2a clinical trial on focal segmental glomerulos...